Evaluation of Early Predictors of Metabolic Syndrome in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Abstract #2770

Introduction: Metabolic syndrome and obesity (MetS) are supposed to have a role in cancer but data analysing their association with GEP-NET are lacking.
Aim(s): Aim of this study was to explore the association of early predictors of MetS with GEP-NET, using as tools Fatty Liver Index (FLI), a predictor of non-alcoholic fatty liver disease (NAFLD) and Visceral Adiposity Index (VAI), a gender-specific indicator of adipose dysfunction.
Materials and methods: A cross-sectional case-control observational study was conducted. VAI and FLI were calculated in GEP-NET patients referred to the ENETS Center of Excellence of Naples, Endocrinology Unity of Federico II University between January 2015 and November 2019, as well as control healthy subjects, age, sex and BMI-matched. VAI is based on waist circumference (WC), body mass index (BMI), triglycerides, and HDL cholesterol levels. FLI is based on BMI, WC, triglycerides and GGT.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD, PhD Roberta Modica

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2815 Unexpected High Rate of Metastases in Type 1 Gastric Neuroendocrine Neoplasia
Introduction: Gastric neuroendocrine neoplasms (gNEN) represent about 7.5% of gastroenteropancreatic NEN (gepNEN), classified in: type 1 (70-80%), related to autoimmune gastritis, type 2 (5%), related to Zollinger-Ellison syndrome in multiple endocrine neoplasia 1 and type 3 (15-20%), in absence of hypergastrinemia or mucosal atrophy.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Filomena Bottiglieri
#2956 Somatostatin Analogs: The Economic Value of Lanreotide Autogel Delivery Attributes in the Treatment of GEP-NET versus Octreotide LAR – A UK Budget Impact Analysis
Introduction: Lanreotide autogel (LAN) and octreotide long acting release (OCT) are long-acting somatostatin analogues (LA-SSAs) used to treat patients (pts) with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). However, the treatments differ in terms of injection route, need for administration by a health care professional and dosing interval.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Marion Feuilly
#2762 Finding the Risk Factors Associated with Neuroendocrine Tumors of Rectum
Introduction: Neuroendocrine tumors usually exhibits aggressive clinical behaviour and exclusive histopathological features. 60 to 70% of rectal NETs are asymptomatic.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Arooj Fatima
Authors: Fatima A, Zai S S A, ...
#2694 The Incidence of Gastrointestinal Neuroendocrine Tumors in the Russian Population
Introduction: Over the past four decades, the incidence of neuroendocrine tumors (NETs) has increased. The limited choice of treatments, broad clinical variability of the syndrome explains the increased interest in NETs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Alina Isiangulova
#2885 Ectopic Neuroendocrine Carcinoma: An Occult Source of ACTH
Introduction: About 250 cases of ectopic ACTH-producing neuroendocrine carcinoma (ACTH-NEC) have been reported; however metastatic ACTH-NEC of unknown primary is very rare. Usually are characterized by having a large cell, small cell, poorly differentiated or anaplastic cell, and Ki-67 index between 40-90%.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: MD Deyanira González Devia